HAL (France)
open access
AhR-dependent ferroptosis as a therapeutic opportunity to counteract BRAFi-resistance in melanoma
Drug resistance limits the achievement of persistent cures for the treatment of melanoma, despite the efficacy of targeted therapies. This study explored how transcriptional regulation governs metabolic adaptations that underlie resistance. Our analysis of the metabolic profiles revealed a distinct
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Hypoxia drives trastuzumab resistance through Rac1 pathway in HER2-positive breast cancer#266267
- Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer#432859
- Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma#1244922
- UCHL5 suppresses thyroid carcinoma progression via ZRANB1 stabilization and ferroptosis regulation.#143184
- Multi-omics data mining combined with experimental validation reveals ferroptosis- and autophagy-associated hub genes as diagnostic candidates and immune modulators in atherosclerosis.#269469
Record · ID 1329376
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive